5 August 2026

To
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

Scrip Code: 543064

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: <u>Press Release</u>

Please find annexed press release on the unaudited financial results of the Company for the quarter ended 30 June 2026.

We request you to take the above on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

SISIRA KUMAR MISHRA
Digitally signed by SISIRA KUMAR MISHRA
Date: 2026.08.05 18:03:25 +05'30'

Sisir K. Mishra
Company Secretary & Compliance Officer

Encl: as above

Cohance Lifesciences Announces Q1FY27 Results

Q1 as guided, Strong Growth rebound in H2

Hyderabad/Mumbai, August 05, 2026

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited), a leading global CDMO (Contract Development and Manufacturing Organization), today announced its unaudited financial results for the first quarter ended June 30, 2026.

Q1FY27 Financial Performance

- Q1FY27 reported revenue from operations of ₹4,223 million, down 23.1% year-on-year. Gross margins contracted to 71.5% from 73.0% in Q1FY26, largely due to product mix and a lower contribution from the CDMO business at 38%, reflecting the lumpy nature of the business and Phasing of orders towards H2.
- Adjusted EBITDA was ₹92 million. The reduction reflects the lower revenue base, negative operating leverage and the impact of subsidiary consolidation. Standalone Adjusted EBITDA margins were at 9.2%.
- The standalone business generated revenue of ₹3,599 million and adjusted EBITDA of ₹332 million, representing a margin of 9.2%. Sapala contributed revenue of approximately ₹274 million, while NJ Bio reported revenue of ₹350 million and an adjusted EBITDA loss.
- Capital expenditure during the quarter was approximately ₹598 million. Consolidated net cash stood at approximately ₹2,512 million as of June 30, 2026.

Mr. Umang Vohra, Executive Chairman and Group CEO, said: *"As we had guided, Q1 has been weak on both revenue and EBITDA and would be our lowest quarter ever. The quarter has played out accordingly. From here, we expect improvement in Q2 and a return to year-on-year growth from the second half, supported by secured orders, scheduled deliveries and progress across our late-stage pipeline. We have also acted on two immediate priorities: building one integrated nucleic-acid business with a clear path to full ownership of Sapala, and repositioning Agrochemicals towards an innovator-product-led portfolio. Underpinning these actions is the One Cohance culture bringing our scientific capabilities, teams and operating practices together around common standards of safety, quality, accountability and customer focus".*

Strategic initiatives:

- Management has acted on two immediate priorities
  - Building one integrated nucleic-acid business with clear leadership and a defined path to full ownership of Sapala.
  - Repositioning Agrochemicals towards a broader innovator-product-led portfolio.

Key Business Highlights of Q1FY27

- Pharma CDMO: Two recently commercialised molecules are scheduled for delivery across Q2 and Q3. A significant restocking order was secured for a commercial molecule affected by inventory destocking in FY26, providing delivery visibility for Q4 FY27 and FY28.
- Late-stage pipeline: One product advanced to Phase III programme and participation expanded in an existing fast-track Phase III programme. The RFQ pipeline strengthened through additional late-stage and commercial enquiries, especially in ADC – payload-linker segments and Oligo.
- ADCs: Execution progressed across payload, payload-linker and bioconjugation programmes. A customised payload order remains on schedule for Q2 delivery, while the expanded MMAE and Exatecan portfolio is seeing encouraging customer interest as innovators diversify supply chains.
- Nucleic acids: Shipments commenced under a specialised building-block programme supporting an orphan-drug candidate. Cohance is aligning R&D, business development, manufacturing and commercial execution around an integrated nucleic-acid offering anchored in Sapala, while progressing GMP operationalisation and validation of priority amidites.
- API+: The API business remained resilient, supported by pricing and product mix. The Company received validation orders for additional product grades, secured two CEP approvals and filed two Korean DMFs. Formulations performance was softer, while remediation and operational normalisation at Nacharam continued in-line with plan.
- Specialty Chemicals: Performance Materials progressed in line with plan. Agrochemicals reflected expected H2-weighted phasing, while an active-ingredient programme advanced into registration and qualification campaigns with Japanese innovators progressed.
- Quality and execution: Multiple customer audits across the Pharma CDMO and API manufacturing network were completed without any critical observation. Commercial OTIF remained at 100% year to date.
- EcoVadis Gold Rating: Cohance's sustainability assessment score progressed from Silver to Gold, reflecting the strength of our environmental, social and governance performance.
- British Safety Council International Safety Award 2026 (Merit) was awarded to our two API sites and two CDMO sites, recognising excellence in health, safety and wellbeing management

-ENDS-

About Cohance Lifesciences

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Leveraging a combined platform with state-of-the-art facilities in India and the U.S., Cohance delivers integrated solutions from early development to commercial supply for leading global pharma companies.

For more information, please contact: www.cohance.com

Cyndrella Carvalho, Head - Investor Relations,

Cohance Lifesciences Limited

Tel: 040 2354 3311

Email: cyndrella.carvalho@cohance.com

Gavin Desa / Konpal Pali

CDR India

Tel: +91 98206 37649

Email: gavin@cdr-india.com; konpal@cdr-india.com